(State or other jurisdiction | (Commission File Number) | (IRS Employer | ||||||||||||
of incorporation) | Identification No.) |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered | ||||||||||||
Emerging growth company | ||||||||||||||||||||||||||
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ |
IDEX CORPORATION | ||||||||
By: | /s/ WILLIAM K. GROGAN | |||||||
William K. Grogan | ||||||||
Senior Vice President and Chief Financial Officer | ||||||||
April 27, 2022 |
Exhibit Number | Description | |||||||
Three Months Ended March 31, | |||||||||||||||||
(Dollars in millions, except per share amounts) | 2022 | 2021 | Increase (Decrease) | ||||||||||||||
Net sales | $ | 751.1 | $ | 652.0 | $ | 99.1 | |||||||||||
Organic net sales growth* | 12 | % | |||||||||||||||
Operating income | 187.6 | 155.5 | 32.1 | ||||||||||||||
Adjusted operating income* | 187.6 | 158.4 | 29.2 | ||||||||||||||
Net income attributable to IDEX | 140.0 | 112.7 | 27.3 | ||||||||||||||
Adjusted net income attributable to IDEX* | 149.8 | 123.4 | 26.4 | ||||||||||||||
Diluted EPS attributable to IDEX | 1.83 | 1.48 | 0.35 | ||||||||||||||
Adjusted diluted EPS attributable to IDEX* | 1.96 | 1.62 | 0.34 | ||||||||||||||
Adjusted EBITDA* | 214.7 | 180.8 | 33.9 | ||||||||||||||
Cash flow from operating activities | 79.7 | 109.3 | (29.6) | ||||||||||||||
Free cash flow* | 63.6 | 94.7 | (31.1) | ||||||||||||||
Gross margin | 45.6 | % | 44.9 | % | 70 bps | ||||||||||||
Adjusted gross margin* | 45.6 | % | 45.0 | % | 60 bps | ||||||||||||
Operating margin | 25.0 | % | 23.9 | % | 110 bps | ||||||||||||
Adjusted operating margin* | 25.0 | % | 24.3 | % | 70 bps | ||||||||||||
Adjusted EBITDA margin* | 28.6 | % | 27.7 | % | 90 bps | ||||||||||||
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. |
Three Months Ended March 31, | |||||||||||||||||
(Dollars in millions) | 2022 | 2021 | Increase (Decrease) | ||||||||||||||
Net sales | $ | 272.0 | $ | 243.3 | $ | 28.7 | |||||||||||
Operating income | 80.4 | 62.9 | 17.5 | ||||||||||||||
Operating margin | 29.5 | % | 25.8 | % | 370 bps | ||||||||||||
Adjusted operating income* | $ | 80.4 | $ | 64.5 | $ | 15.9 | |||||||||||
Adjusted operating margin* | 29.5 | % | 26.5 | % | 300 bps | ||||||||||||
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. |
Three Months Ended March 31, | |||||||||||||||||
(Dollars in millions) | 2022 | 2021 | Increase (Decrease) | ||||||||||||||
Net sales | $ | 315.2 | $ | 250.4 | $ | 64.8 | |||||||||||
Operating income | 83.6 | 66.6 | 17.0 | ||||||||||||||
Operating margin | 26.5 | % | 26.6 | % | (10) bps | ||||||||||||
Adjusted operating income* | $ | 83.6 | $ | 67.2 | $ | 16.4 | |||||||||||
Adjusted operating margin* | 26.5 | % | 26.9 | % | (40) bps | ||||||||||||
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. |
Three Months Ended March 31, | |||||||||||||||||
(Dollars in millions) | 2022 | 2021 | Increase (Decrease) | ||||||||||||||
Net sales | $ | 164.7 | $ | 159.5 | $ | 5.2 | |||||||||||
Operating income | 40.5 | 44.6 | (4.1) | ||||||||||||||
Operating margin | 24.6 | % | 27.9 | % | (330) bps | ||||||||||||
Adjusted operating income* | $ | 40.5 | $ | 44.7 | $ | (4.2) | |||||||||||
Adjusted operating margin* | 24.6 | % | 28.0 | % | (340) bps | ||||||||||||
*These are non-GAAP measures. See the definitions of these non-GAAP measures in the section in this release titled “Non-GAAP Measures of Financial Performance” and reconciliations to their most directly comparable GAAP financial measures in the reconciliation tables at the end of this release. |
Three Months Ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Net sales | $ | 751.1 | $ | 652.0 | |||||||
Cost of sales | 408.6 | 359.4 | |||||||||
Gross profit | 342.5 | 292.6 | |||||||||
Selling, general and administrative expenses | 154.3 | 134.9 | |||||||||
Restructuring expenses and asset impairments | 0.6 | 2.2 | |||||||||
Operating income | 187.6 | 155.5 | |||||||||
Other income - net | (2.3) | (0.8) | |||||||||
Interest expense | 9.5 | 10.7 | |||||||||
Income before income taxes | 180.4 | 145.6 | |||||||||
Provision for income taxes | 40.5 | 32.9 | |||||||||
Net income | $ | 139.9 | $ | 112.7 | |||||||
Net loss attributable to noncontrolling interest | 0.1 | — | |||||||||
Net income attributable to IDEX | $ | 140.0 | $ | 112.7 | |||||||
Earnings per Common Share: | |||||||||||
Basic earnings per common share attributable to IDEX | $ | 1.84 | $ | 1.48 | |||||||
Diluted earnings per common share attributable to IDEX | $ | 1.83 | $ | 1.48 | |||||||
Share Data: | |||||||||||
Basic weighted average common shares outstanding | 76.1 | 75.9 | |||||||||
Diluted weighted average common shares outstanding | 76.4 | 76.3 |
March 31, 2022 | December 31, 2021 | ||||||||||
Assets | |||||||||||
Current assets | |||||||||||
Cash and cash equivalents | $ | 733.2 | $ | 855.4 | |||||||
Receivables - net | 411.2 | 356.4 | |||||||||
Inventories | 428.5 | 370.4 | |||||||||
Other current assets | 108.4 | 95.8 | |||||||||
Total current assets | 1,681.3 | 1,678.0 | |||||||||
Property, plant and equipment - net | 325.8 | 327.3 | |||||||||
Goodwill and intangible assets | 2,842.7 | 2,765.0 | |||||||||
Other noncurrent assets | 149.9 | 146.9 | |||||||||
Total assets | $ | 4,999.7 | $ | 4,917.2 | |||||||
Liabilities and equity | |||||||||||
Current liabilities | |||||||||||
Trade accounts payable | $ | 210.2 | $ | 178.8 | |||||||
Accrued expenses | 258.1 | 259.8 | |||||||||
Dividends payable | — | 41.4 | |||||||||
Total current liabilities | 468.3 | 480.0 | |||||||||
Long-term borrowings | 1,190.6 | 1,190.3 | |||||||||
Other noncurrent liabilities | 441.9 | 443.8 | |||||||||
Total liabilities | 2,100.8 | 2,114.1 | |||||||||
Shareholders' equity | 2,899.0 | 2,803.1 | |||||||||
Noncontrolling interest | (0.1) | — | |||||||||
Total equity | 2,898.9 | 2,803.1 | |||||||||
Total liabilities and equity | $ | 4,999.7 | $ | 4,917.2 |
Three Months Ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Cash flows from operating activities | |||||||||||
Net income | $ | 139.9 | $ | 112.7 | |||||||
Adjustments to reconcile net income to net cash provided by operating activities: | |||||||||||
Gains on sales of assets | (2.7) | — | |||||||||
Asset impairments | — | 0.1 | |||||||||
Depreciation and amortization | 12.2 | 10.6 | |||||||||
Amortization of intangible assets | 15.3 | 11.0 | |||||||||
Amortization of debt issuance expenses | 0.4 | 0.4 | |||||||||
Share-based compensation expense | 6.6 | 6.2 | |||||||||
Deferred income taxes | 1.0 | 0.5 | |||||||||
Non-cash interest expense associated with forward starting swaps | — | 0.9 | |||||||||
Changes in (net of the effect from acquisitions/divestitures and foreign exchange): | |||||||||||
Receivables | (49.0) | (46.3) | |||||||||
Inventories | (50.2) | (7.5) | |||||||||
Other current assets | (12.7) | 3.3 | |||||||||
Trade accounts payable | 28.1 | 20.0 | |||||||||
Deferred revenue | 6.4 | 11.1 | |||||||||
Accrued expenses | (16.3) | (11.1) | |||||||||
Other - net | 0.7 | (2.6) | |||||||||
Net cash flows provided by operating activities | 79.7 | 109.3 | |||||||||
Cash flows from investing activities | |||||||||||
Purchases of property, plant and equipment | (16.1) | (14.6) | |||||||||
Acquisition of businesses, net of cash acquired | (114.7) | (106.2) | |||||||||
Proceeds from disposal of fixed assets | 6.5 | 0.2 | |||||||||
Other - net | (0.1) | 1.1 | |||||||||
Net cash flows used in investing activities | (124.4) | (119.5) | |||||||||
Cash flows from financing activities | |||||||||||
Dividends paid | (41.4) | (38.1) | |||||||||
Proceeds from stock option exercises | 1.4 | 3.2 | |||||||||
Repurchases of common stock | (26.3) | — | |||||||||
Shares surrendered for tax withholding | (4.9) | (5.4) | |||||||||
Other - net | (0.1) | (0.1) | |||||||||
Net cash flows used in financing activities | (71.3) | (40.4) | |||||||||
Effect of exchange rate changes on cash and cash equivalents | (6.2) | (17.2) | |||||||||
Net decrease in cash | (122.2) | (67.8) | |||||||||
Cash and cash equivalents at beginning of year | 855.4 | 1,025.9 | |||||||||
Cash and cash equivalents at end of period | $ | 733.2 | $ | 958.1 |
Three Months Ended March 31, (a) | ||||||||||||||
2022 | 2021 | |||||||||||||
Fluid & Metering Technologies | ||||||||||||||
Net sales | $ | 272.0 | $ | 243.3 | ||||||||||
Operating income (b) | 80.4 | 62.9 | ||||||||||||
Operating margin | 29.5 | % | 25.8 | % | ||||||||||
EBITDA(c) | $ | 89.6 | $ | 70.0 | ||||||||||
EBITDA margin(c) | 32.9 | % | 28.7 | % | ||||||||||
Depreciation and amortization | $ | 7.6 | $ | 7.1 | ||||||||||
Capital expenditures | 4.9 | 3.3 | ||||||||||||
Health & Science Technologies | ||||||||||||||
Net sales | $ | 315.2 | $ | 250.4 | ||||||||||
Operating income (b) | 83.6 | 66.6 | ||||||||||||
Operating margin | 26.5 | % | 26.6 | % | ||||||||||
EBITDA(c) | $ | 99.8 | $ | 77.5 | ||||||||||
EBITDA margin(c) | 31.7 | % | 31.0 | % | ||||||||||
Depreciation and amortization | $ | 16.0 | $ | 10.5 | ||||||||||
Capital expenditures | 9.2 | 9.1 | ||||||||||||
Fire & Safety/Diversified Products | ||||||||||||||
Net sales | $ | 164.7 | $ | 159.5 | ||||||||||
Operating income (b) | 40.5 | 44.6 | ||||||||||||
Operating margin | 24.6 | % | 27.9 | % | ||||||||||
EBITDA(c) | $ | 45.9 | $ | 48.8 | ||||||||||
EBITDA margin(c) | 27.9 | % | 30.5 | % | ||||||||||
Depreciation and amortization | $ | 3.8 | $ | 3.9 | ||||||||||
Capital expenditures | 2.0 | 1.8 | ||||||||||||
Corporate Office and Eliminations | ||||||||||||||
Intersegment sales eliminations | $ | (0.8) | $ | (1.2) | ||||||||||
Operating income (b) | (16.9) | (18.6) | ||||||||||||
EBITDA(c) | (17.9) | (18.4) | ||||||||||||
Depreciation and amortization (d) | 0.1 | 0.1 | ||||||||||||
Capital expenditures | — | 0.4 | ||||||||||||
Company | ||||||||||||||
Net sales | $ | 751.1 | $ | 652.0 | ||||||||||
Operating income | 187.6 | 155.5 | ||||||||||||
Operating margin | 25.0 | % | 23.9 | % | ||||||||||
EBITDA(c) | $ | 217.4 | $ | 177.9 | ||||||||||
EBITDA margin(c) | 28.9 | % | 27.3 | % | ||||||||||
Depreciation and amortization (d) | $ | 27.5 | $ | 21.6 | ||||||||||
Capital expenditures | 16.1 | 14.6 |
Three Months Ended March 31, (a) | ||||||||||||||
2022 | 2021 | |||||||||||||
Fluid & Metering Technologies | ||||||||||||||
Net sales | $ | 272.0 | $ | 243.3 | ||||||||||
Adjusted operating income (b)(c) | 80.4 | 64.5 | ||||||||||||
Adjusted operating margin(c) | 29.5 | % | 26.5 | % | ||||||||||
Adjusted EBITDA(c) | $ | 88.4 | $ | 71.6 | ||||||||||
Adjusted EBITDA margin(c) | 32.5 | % | 29.4 | % | ||||||||||
Depreciation and amortization | $ | 7.6 | $ | 7.1 | ||||||||||
Capital expenditures | 4.9 | 3.3 | ||||||||||||
Health & Science Technologies | ||||||||||||||
Net sales | $ | 315.2 | $ | 250.4 | ||||||||||
Adjusted operating income (b)(c) | 83.6 | 67.2 | ||||||||||||
Adjusted operating margin(c) | 26.5 | % | 26.9 | % | ||||||||||
Adjusted EBITDA(c) | $ | 99.8 | $ | 78.1 | ||||||||||
Adjusted EBITDA margin(c) | 31.7 | % | 31.2 | % | ||||||||||
Depreciation and amortization | $ | 16.0 | $ | 10.5 | ||||||||||
Capital expenditures | 9.2 | 9.1 | ||||||||||||
Fire & Safety/Diversified Products | ||||||||||||||
Net sales | $ | 164.7 | $ | 159.5 | ||||||||||
Adjusted operating income (b)(c) | 40.5 | 44.7 | ||||||||||||
Adjusted operating margin(c) | 24.6 | % | 28.0 | % | ||||||||||
Adjusted EBITDA(c) | $ | 44.4 | $ | 48.9 | ||||||||||
Adjusted EBITDA margin(c) | 26.9 | % | 30.6 | % | ||||||||||
Depreciation and amortization | $ | 3.8 | $ | 3.9 | ||||||||||
Capital expenditures | 2.0 | 1.8 | ||||||||||||
Corporate Office and Eliminations | ||||||||||||||
Intersegment sales eliminations | $ | (0.8) | $ | (1.2) | ||||||||||
Adjusted operating income (b)(c) | (16.9) | (18.0) | ||||||||||||
Adjusted EBITDA(c) | (17.9) | (17.8) | ||||||||||||
Depreciation and amortization(d) | 0.1 | 0.1 | ||||||||||||
Capital expenditures | — | 0.4 | ||||||||||||
Company | ||||||||||||||
Net sales | $ | 751.1 | $ | 652.0 | ||||||||||
Adjusted operating income(c) | 187.6 | 158.4 | ||||||||||||
Adjusted operating margin(c) | 25.0 | % | 24.3 | % | ||||||||||
Adjusted EBITDA(c) | $ | 214.7 | $ | 180.8 | ||||||||||
Adjusted EBITDA margin(c) | 28.6 | % | 27.7 | % | ||||||||||
Depreciation and amortization (d) | $ | 27.5 | $ | 21.6 | ||||||||||
Capital expenditures | 16.1 | 14.6 | ||||||||||||
(a) | Three month data includes the results of the ABEL Pumps acquisition (March 2021) in the Fluid & Metering Technologies segment and the Airtech acquisition (June 2021) in the Health & Science Technologies segment from the date of acquisition. Three month data also includes the results of CiDRA Precision Services (March 2021) in the Health & Science Technologies segment through the date of disposition. | |||||||||||||
(b) | Segment operating income excludes unallocated corporate operating expenses which are included in Corporate Office and Eliminations. | |||||||||||||
(c) | These are non-GAAP financial measures. For a reconciliation of these non-GAAP financial measures to their most comparable measure calculated and presented in accordance with GAAP, see the reconciliation tables below. | |||||||||||||
(d) | Depreciation and amortization excludes amortization of debt issuance costs. |
Three Months Ended March 31, 2022 | |||||||||||||||||||||||
FMT | HST | FSDP | IDEX | ||||||||||||||||||||
Change in net sales | 12 | % | 26 | % | 3 | % | 15 | % | |||||||||||||||
- Net impact from acquisitions/divestitures | 2 | % | 11 | % | — | % | 5 | % | |||||||||||||||
- Impact from foreign currency | (1 | %) | (1 | %) | (2 | %) | (2 | %) | |||||||||||||||
Change in organic net sales | 11 | % | 16 | % | 5 | % | 12 | % |
Three Months Ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Gross profit | $ | 342.5 | $ | 292.6 | |||||||
+ Fair value inventory step-up charge | — | 0.7 | |||||||||
Adjusted gross profit | $ | 342.5 | $ | 293.3 | |||||||
Net sales | $ | 751.1 | $ | 652.0 | |||||||
Gross margin | 45.6 | % | 44.9 | % | |||||||
Adjusted gross margin | 45.6 | % | 45.0 | % |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMT | HST | FSDP | Corporate | IDEX | FMT | HST | FSDP | Corporate | IDEX | ||||||||||||||||||||||||||||||||||||||||||||||||||
Reported operating income (loss) | $ | 80.4 | $ | 83.6 | $ | 40.5 | $ | (16.9) | $ | 187.6 | $ | 62.9 | $ | 66.6 | $ | 44.6 | $ | (18.6) | $ | 155.5 | |||||||||||||||||||||||||||||||||||||||
+ Restructuring expenses and asset impairments | — | — | — | — | — | 0.9 | 0.6 | 0.1 | 0.6 | 2.2 | |||||||||||||||||||||||||||||||||||||||||||||||||
+ Fair value inventory step-up charge | — | — | — | — | — | 0.7 | — | — | — | 0.7 | |||||||||||||||||||||||||||||||||||||||||||||||||
Adjusted operating income (loss) | $ | 80.4 | $ | 83.6 | $ | 40.5 | $ | (16.9) | $ | 187.6 | $ | 64.5 | $ | 67.2 | $ | 44.7 | $ | (18.0) | $ | 158.4 | |||||||||||||||||||||||||||||||||||||||
Net sales (eliminations) | $ | 272.0 | $ | 315.2 | $ | 164.7 | $ | (0.8) | $ | 751.1 | $ | 243.3 | $ | 250.4 | $ | 159.5 | $ | (1.2) | $ | 652.0 | |||||||||||||||||||||||||||||||||||||||
Reported operating margin | 29.5 | % | 26.5 | % | 24.6 | % | n/m | 25.0 | % | 25.8 | % | 26.6 | % | 27.9 | % | n/m | 23.9 | % | |||||||||||||||||||||||||||||||||||||||||
Adjusted operating margin | 29.5 | % | 26.5 | % | 24.6 | % | n/m | 25.0 | % | 26.5 | % | 26.9 | % | 28.0 | % | n/m | 24.3 | % |
Three Months Ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Reported net income attributable to IDEX | $ | 140.0 | $ | 112.7 | |||||||
+ Restructuring expenses and asset impairments | — | 2.2 | |||||||||
+ Tax impact on restructuring expenses and asset impairments | — | (0.5) | |||||||||
+ Fair value inventory step-up charge | — | 0.7 | |||||||||
+ Tax impact on fair value inventory step-up charge | — | (0.2) | |||||||||
- Gains on sales of assets | (2.7) | — | |||||||||
+ Tax impact on gains on sales of assets | 0.6 | — | |||||||||
+ Acquisition-related intangible asset amortization | 15.3 | 11.0 | |||||||||
+ Tax impact on acquisition-related intangible asset amortization | (3.4) | (2.5) | |||||||||
Adjusted net income attributable to IDEX | $ | 149.8 | $ | 123.4 |
Three Months Ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Reported diluted EPS attributable to IDEX | $ | 1.83 | $ | 1.48 | |||||||
+ Restructuring expenses and asset impairments | — | 0.03 | |||||||||
+ Tax impact on restructuring expenses and asset impairments | — | (0.01) | |||||||||
+ Fair value inventory step-up charge | — | 0.01 | |||||||||
+ Tax impact on fair value inventory step-up charge | — | — | |||||||||
- Gains on sales of assets | (0.03) | — | |||||||||
+ Tax impact on gains on sales of assets | 0.01 | — | |||||||||
+ Acquisition-related intangible asset amortization | 0.20 | 0.14 | |||||||||
+ Tax impact on acquisition-related intangible asset amortization | (0.05) | (0.03) | |||||||||
Adjusted diluted EPS attributable to IDEX | $ | 1.96 | $ | 1.62 | |||||||
Diluted weighted average shares outstanding | 76.4 | 76.3 |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMT | HST | FSDP | Corporate | IDEX | FMT | HST | FSDP | Corporate | IDEX | ||||||||||||||||||||||||||||||||||||||||||||||||||
Reported operating income (loss) | $ | 80.4 | $ | 83.6 | $ | 40.5 | $ | (16.9) | $ | 187.6 | $ | 62.9 | $ | 66.6 | $ | 44.6 | $ | (18.6) | $ | 155.5 | |||||||||||||||||||||||||||||||||||||||
+ Other income (expense), net | 1.6 | 0.2 | 1.6 | (1.1) | 2.3 | — | 0.4 | 0.3 | 0.1 | 0.8 | |||||||||||||||||||||||||||||||||||||||||||||||||
+ Depreciation and amortization | 7.6 | 16.0 | 3.8 | 0.1 | 27.5 | 7.1 | 10.5 | 3.9 | 0.1 | 21.6 | |||||||||||||||||||||||||||||||||||||||||||||||||
EBITDA | 89.6 | 99.8 | 45.9 | (17.9) | 217.4 | 70.0 | 77.5 | 48.8 | (18.4) | 177.9 | |||||||||||||||||||||||||||||||||||||||||||||||||
- Interest expense | 9.5 | 10.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- Provision for income taxes | 40.5 | 32.9 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
- Depreciation and amortization | 27.5 | 21.6 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reported net income | $ | 139.9 | $ | 112.7 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net sales (eliminations) | $ | 272.0 | $ | 315.2 | $ | 164.7 | $ | (0.8) | $ | 751.1 | $ | 243.3 | $ | 250.4 | $ | 159.5 | $ | (1.2) | $ | 652.0 | |||||||||||||||||||||||||||||||||||||||
Reported operating margin | 29.5 | % | 26.5 | % | 24.6 | % | n/m | 25.0 | % | 25.8 | % | 26.6 | % | 27.9 | % | n/m | 23.9 | % | |||||||||||||||||||||||||||||||||||||||||
EBITDA margin | 32.9 | % | 31.7 | % | 27.9 | % | n/m | 28.9 | % | 28.7 | % | 31.0 | % | 30.5 | % | n/m | 27.3 | % | |||||||||||||||||||||||||||||||||||||||||
EBITDA interest coverage | 22.9 | 16.5 |
Three Months Ended March 31, | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
2022 | 2021 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
FMT | HST | FSDP | Corporate | IDEX | FMT | HST | FSDP | Corporate | IDEX | ||||||||||||||||||||||||||||||||||||||||||||||||||
EBITDA(1) | $ | 89.6 | $ | 99.8 | $ | 45.9 | $ | (17.9) | $ | 217.4 | $ | 70.0 | $ | 77.5 | $ | 48.8 | $ | (18.4) | $ | 177.9 | |||||||||||||||||||||||||||||||||||||||
+ Restructuring expenses and asset impairments | — | — | — | — | — | 0.9 | 0.6 | 0.1 | 0.6 | 2.2 | |||||||||||||||||||||||||||||||||||||||||||||||||
+ Fair value inventory step-up charge | — | — | — | — | — | 0.7 | — | — | — | 0.7 | |||||||||||||||||||||||||||||||||||||||||||||||||
- Gains on sales of assets | (1.2) | — | (1.5) | — | (2.7) | — | — | — | — | — | |||||||||||||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA | $ | 88.4 | $ | 99.8 | $ | 44.4 | $ | (17.9) | $ | 214.7 | $ | 71.6 | $ | 78.1 | $ | 48.9 | $ | (17.8) | $ | 180.8 | |||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA margin | 32.5 | % | 31.7 | % | 26.9 | % | n/m | 28.6 | % | 29.4 | % | 31.2 | % | 30.6 | % | n/m | 27.7 | % | |||||||||||||||||||||||||||||||||||||||||
Adjusted EBITDA interest coverage | 22.6 | 16.8 |
Three Months Ended March 31, | |||||||||||
2022 | 2021 | ||||||||||
Cash flows from operating activities | $ | 79.7 | $ | 109.3 | |||||||
- Capital expenditures | 16.1 | 14.6 | |||||||||
Free cash flow | $ | 63.6 | $ | 94.7 |
Guidance | ||||||||||||||
Second Quarter 2022 | Full Year 2022 | |||||||||||||
Estimated EPS attributable to IDEX | $1.69 - $1.74 | $6.87 - $7.00 | ||||||||||||
+ Acquisition-related intangible asset amortization | $0.22 | $0.85 | ||||||||||||
+ Tax impact on acquisition-related intangible asset amortization | $(0.06) | $(0.20) | ||||||||||||
- Gains on sales of assets | — | $(0.03) | ||||||||||||
+ Tax impact on gains on sales of assets | — | $0.01 | ||||||||||||
Estimated adjusted EPS attributable to IDEX | $1.85 - $1.90 | $7.50 - $7.63 |
>81&-/+7R8R(QP" 0Q%)@>P_"[P+#X!T2&R51]KF59;R3N\S#)7/]
MR+/EQCI@%OO,Q+7<#T:F(Y+Q[IT6J^'M2M)P"DEE<=2 %98V='R>!L=5<$\
MC-)[#1\C_LNZ1]IUN]U(C*V=H(P?1[B0;3]=D,@^A-+J!]RU0@H * "@#&U[
MP_8>)K-].U6%+FVDZHXZ$=&5AAD)S_ +7JM1GG\G@/XF_#M=^F27,MO$.EC<-/%Q_TZ/AF]O\
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M4%+9!90M],F-EZ _'$WBG2)[34KE[K4K2=F;S7+2M;R*AC
M?).2H?>AQPN%SC<,BTT ^@J8CY<_:6\8V4&E)X;B9);ZXFCFD08)@ACRP9C_
M O(^T*O4Q[R< KNG]!GJ7P:\.3>%_"EE:72F.XD5[B5#D%3.YD52#]UEC**
MZ]G# \TUW ]$U'4;?2+:6^O'$-O;HTDLASA$499B "3@=@"3V!-/81@^&O&^
MB^,#*-%NEO/LVSS=B2*$\S=LR711\VQ\ 9/RFD/8ZNF(* "@ H * /(/B=?9
M>WLE/0-,P^OR)_)_SKV<%#XJGR7YO]#AKO:/S_K\3RBO8.(* "@ H * "@ H
M * "@#UOX86/_'Q>D?W85/\ X^X_]%UXV-E\-/YO\E^IW4%O+Y?Y_H>LLP0%
MF. !DGT ZUXYVGRUJEZ=1NYKH_\ +61G'L"3M'X# _"OK:9PC#LDOGU_$\
M:3YFWW90K0D* "@ H * "@ H 'Z=9Q76HL95
M!V]*W@[.YC)71SMIHMQ<(9'78@'4TL,8B8IUP<5W.I(L-D^T8 7M7$0'<6/O
M6V'FY2,<0K1+L57$Z54B%7$KV*9Y-0E%&>:.U,&L9]-O5$EO=1M$
MZD=F&,CT93AE/56 8<@4O(-CXO\ V7I98O$-];*=T#6#,Q&=I>.XA6,C..JR
M2XR,X].009]R4Q!0!6N;R"S7?<2)"OK(ZH.PZL0.I _$>M*Z6^@>@ZWNH;I=
M\#I*O]Y#\U)%%UT GI@% 'S!^U'J_V71;+3%.&O+II6'M*Z6^@>@MO=0W:[[>1)4_O(RL/S4D4)KH&Q
M8I@% !0 4 48]3M)9/)CGA:0=461"PS_ +(.>X[=Z5UW0[%ZF(* "@"*:>.W
M7?*RQH.K,0H'XD@4MMP(+6_MKW/V:6*;'7RW5\8QUVD^H_,>M%T]A[%RF(*
M"@ H * "@ H * "@#S7XEWWDV<5HIP9Y-Q'^S&/_ (IE/X5ZF"C>;G_*OQ?_
M +G)7=HJ/=_D>)U[IYX4 % !0 4 % !0 4 % 'HOPVL?/OWNB/EMHSCV>3Y
M1_XZ'KS,9+E@H+[3_!?\&QU4%[S?9?G_ $SW&O!/1/FWQ;??VAJEQ(#E4?RU
M],1_)Q[$@M^-?3X>')2BNZN_GK^6AY51\TF_E]QS==1B% !0 4 % !0 4 %
M!0 4 % !0 4 % !0!WGP\U'['J7V=CA+I"GMO7YD/Z,H_P!ZO.QD.:GS+>+O
M\GH_T^XZ:,K2MW/:M4U&+2;62[F^[$N<=V/15'NQP!]>>*\.$'4DH1W?]7/0
ME)03D^A\R7U[+J,[W4YS)*Q8^G/0#T & !V KZJ$53BH1V1Y#;DVV5*LD*
M"@ H * "@ H * "@ H VM.\/:AJHW6L#NG]\X5/P=RJG'?!)K"=:G2TG))]M
MW]R-(PE+X5^AOCX>:L1G;$/8R#^@(KF^N4O/[C7V,_+[Q?\ A7>K>D7_ '\'
M^%'URE_>^[_@A[&?E]X?\*[U;TB_[^#_ H^N4O[WW?\$/8S\OO(V^'VKKTC
MC;Z2+_4BFL72[M?(7L9KI^(S_A -8_YY)_W]C_\ BJ?UNEW?W,/8S[?B@_X0
M#6/^>2?]_8__ (JCZW2[O[F'L9]OQ1Z)X&\-SZ<EXH264JJ@,&PB@G.5R/
MF8\C_9%>9B:T:KBH;*_EJ_\ AOQ.JE!PNY;L[^O/.D* /+OB/H?G1+J<0^:+
M"2X[H3\K?\!8X/LP[+7K8.KRMTGL]5Z]?O7Y>9QUX:W 'XUS^PI_R1^XTYY=W]XO_ DVJ_\ /U/_
M -_&_P :/84OY(_<'/+^9_>'_"3:K_S]3_\ ?QO\:/84OY(_<'/+^9_>'_"3
M:K_S]3_]_&_QH]A2_DC]P<\OYG]X?\)-JO\ S]3_ /?QO\:/84OY(_<'/+^9
M_>'_ DVJ_\ /U/_ -_&_P :/84OY(_<'/+^9_>'_"3:K_S]3_\ ?QO\:/84
MOY(_<'/+^9_>:NAZMJNJ7T-I]JGQ(XW?O&^X/F<]>R@UC5ITJ<)3Y(Z+33J]
M%^)<)2E)1N_O/H2OG#U H * "@#S?XB:)]KM1J$0_>VW#XZF(G_V1CGV4L3T
MKT\)5Y)>S>TMO7_@[>MCEK0NN9;K\CQ&O>/."@ H * "@ H * "@ H * "@
MH * "@#U/P9X+^T;=1U!?W?#11,/O^CN/[G=5/WNI^7 ;R,3B;7I4GKU?;R7
MGW?3UV[*5+[4MNB/8J\4[Q: "@ H * "@ H * "@ H * /#/V@YW;PW'I^
MMU:_M+10.Y+F8<=QNB4?4BI>GYC1[9:VZ6<*6\0Q'"BQJ/14 4?H!36F@B>F
M 4 % !0 4 % !0 4 ?"'C'_BM?BK'8CYX8;RUMR.O[NV59+@?]]+-]._2H[^
M?_#%;'W?5DA0!!2 ]=_P"&5+3_ *"LW_@*G_QZF ?\,J6G
M_05F_P# 5/\ X]0 H_94L\\ZK-C_ *]D'_M8_P J-0/K".-85$:#"H H'H ,
M ?E3VT$?$/B/_BJ/B]#:R'=%;7=LBJNO#1YZL5T6OW;?C8QJOE@_/3[_ /@'SK7TQY04 % !0 4
M% !0 4 % '4>#;'[?JL"$96-O-;Z1C
V #Z!XI
M/Q)H7]?U\P/H2F(^*]-_XK#XP2S?>AT^>0GN%%C!Y"D>QN%4_P# JC_/^OP1
M1]J59)2U*^CTRTFO9O\ 5VT4DS_[L:%V_0&D] /D7]F*QDU#4=6UZXYD*I%O
M/\3W$C338/7@Q1D^NX=>:2TT709]CU0CR;XX:O\ V-X.U!U.'N42U4=,^?(J
M2#_OT9#^';J$^W]=QHYO]F_1_P"S?":W1&&U"YGGST.U"+=1],PLP_WL]Z$!
M[7K&HIH]C TV3[
M9%\KM XC#$=2T,J[HF]5WL,YQM'RAZ]!&7JWQH\5?$C=I'@_3Y;59OW;S1DR
MS -US-M2&U4C(+M\PZK(II>OW#/7OA!\'HO $9U'4"MQK$Z[6=L_ NKW9&81"I_BE8+^:C<__ ([7/+%4H[._DE_PR_$T5*;Z6]3N=*^&
MMO!A[^0SG_GFF43Z%OOL/ILK@GC)/2FN7S>K_P E^)TQH)?$[^6W]?@>BVMI
M#8QB&W18HUZ*@ 'UXZD]R>3WKS)2E*7O"C%1V+FJ07%I>Q>6R2(_1T.1GTJEJ6L2K;[",'H)Y&&:L1V,<:\#GUI)$"KCK4]>HZBL]T 1AD <538Y/ Q5TI\UTMD95HF_8PP:O P2(?:O^6B XW#^\/2M&W\
M*36<@><.5/ )XK)\-PLVH;PQ5E&5;^=>U>$M9@U(R:3J*1N!'M&[H^#^A%<]
M:2FW33L2DZ:YDM#E='T];